Substudy 06C: A Study of Investigational Agents With Pembrolizumab (MK-3475) and Chemotherapy in Participants With First-Line Locally Advanced Unresectable/Metastatic Gastroesophageal Adenocarcinoma (MK-3475-06C/KEYMAKER-U06)
for Gastroesophageal Junction
8 locations incl. Tucson
Sponsor: Merck Sharp & Dohme LLC
Sex: All·Age: 18+
Code: NCT06469944·Phase 1, Phase 2·Recruiting